
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals has demonstrated strong financial growth, reporting total revenue of $230 million for the first quarter of 2026, reflecting an 11% quarter-over-quarter increase and a 23% year-over-year growth, largely driven by its Precision Medicine unit. The company has experienced a 16% quarter-over-quarter growth in precision medicine revenue, attributed to increased uptake of Gozellix and sustained demand for Illuccix, which positions Telix favorably in the imaging and treatment landscape for prostate cancer. Additionally, potential regulatory milestones, including reimbursement securement in European markets and anticipated marketing approval in China, could further enhance growth prospects and solidify Telix's competitive advantage in the radiopharmaceutical sector.
Bears say
Telix Pharmaceuticals faces several critical risks that contribute to a negative outlook on its stock, primarily stemming from potential negative clinical results with its lead therapeutic asset, TLX591, and delays in advancing pipeline candidates into crucial registrational programs. Additionally, there are concerns regarding the company's ability to secure timely regulatory approvals, alongside competitive pressures from alternative radiopharmaceuticals and modalities that may hinder its market position. The presence of long-term dilution risk further compounds these issues, emphasizing uncertainties related to future earnings and overall financial stability.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares